tradingkey.logo

Dare Bioscience Inc

DARE
View Detailed Chart
1.690USD
+0.010+0.60%
Close 02/06, 16:00ETQuotes delayed by 15 min
23.54MMarket Cap
LossP/E TTM

Dare Bioscience Inc

1.690
+0.010+0.60%
Intraday
1m
30m
1h
D
W
M
D

Today

+0.60%

5 Days

-6.63%

1 Month

-13.78%

6 Months

-25.22%

Year to Date

-12.44%

1 Year

-44.22%

View Detailed Chart

TradingKey Stock Score of Dare Bioscience Inc

Currency: USD Updated: 2026-02-06

Key Insights

Dare Bioscience Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 105 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 10.75.In the medium term, the stock price is expected to remain stable.The company has shown weak stock market performance over the past month, in line with its weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Dare Bioscience Inc's Score

Industry at a Glance

Industry Ranking
105 / 159
Overall Ranking
300 / 4521
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive

Dare Bioscience Inc Highlights

StrengthsRisks
Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.
Growing
The company is in a growing phase, with the latest annual income totaling USD 9.78K.
Overvalued
The company’s latest PE is -0.93, at a high 3-year percentile range.
Held by The Vanguard
Star Investor The Vanguard holds 523.05K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.66.

Analyst Rating

Based on 4 analysts
Buy
Current Rating
10.750
Target Price
+539.88%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Dare Bioscience Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Dare Bioscience Inc Info

Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.
Ticker SymbolDARE
CompanyDare Bioscience Inc
CEOJohnson (Sabrina Martucci)
Websitehttps://www.darebioscience.com/
KeyAI